Significance of Inflammatory Biomarkers in Peripheral Arterial Disease Diagnosis and Prognosis
Alexandr Ceasovschih*, Victorita Sorodoc and Laurentiu Sorodoc
Department of Internal Medicine, Clinical Emergency Hospital “Sfantul Spiridon”, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania
*Corresponding Author: Alexandr Ceasovschih, Department of Internal Medicine, Clinical Emergency Hospital “Sfantul Spiridon”, Faculty of Medicine, Grigore T. Popa University of Medicine and Pharmacy, Iasi, Romania.
Received: March 24, 2022; Published: June , 2022
PAD: Peripheral Arterial Disease
Peripheral arterial disease (PAD) is a widespread group of vascular diseases, due to arterial stenosis or occlusion, in which blood flow in the affected limbs is reduced. It is estimated that PAD affects more than 230 million people worldwide. Due to the large number of asymptomatic PAD cases (>50% of PAD patients), it is difficult to accurately estimate the PAD prevalence. PAD is associated with traditional atherosclerosis risk factors, including age, smoking, dyslipidemia, arterial hypertension, diabetes mellitus, etc. In women, the PAD incidence is similar only in old age, whereas in patients under 65 years - it is reduced by about half, compared to men [1-6].
Keywords: Peripheral Arterial Disease; Atherosclerosis; Inflammation; Biomarkers; Diagnosis; Prognosis
- Aboyans V., et al. “2017 ESC Guidelines on the Diagnosis and Treatment of Peripheral Arterial Diseases, in collaboration with the European Society for Vascular Surgery (ESVS)”. European Heart Journal 39 (2018): 763-816.
- Shu J., et al. “Update on peripheral artery disease: Epidemiology and evidence-based facts”. Atherosclerosis 275 (2018): 379-381.
- Ceasovschih A., et al. “Study Of Cardiovascular Risk Factors In Patients With Peripheral Artery Disease”. Atherosclerosis 287 (2019): E190.
- Aday AW., et al. “Epidemiology of Peripheral Artery Disease and Polyvascular Disease”. Circulation Research12 (2021): 1818-1832.
- Ceasovschih A., et al. “Practical significance of non-invasive diagnosis score in peripheral artery disease: study on 1200 patients”. Atherosclerosis 263 (2017): E186-E186.
- Ceasovschih A., et al. “Peripheral artery disease particularities in women: a prospective study”. Atherosclerosis 315 (2020): e168.
- Funk SD., et al. “Ephs and ephrins resurface in inflammation, immunity, and atherosclerosis”. Pharmacology Research1 (2013): 42-52.
- Ceasovschih A., et al. “Up to date in managementul bolii arteriale periferice. De la ghiduri la practică”. Revista Medicală Română1 (2017): 38-42.
- Krishna SM., et al. “A Review of the Pathophysiology and Potential Biomarkers for Peripheral Artery Disease”. International Journal of Molecular Sciences5 (2015): 11294-11322.
- Ceasovschih A., et al. “Biomarker Utility for Peripheral Artery Disease Diagnosis in Real Clinical Practice: A Prospective Study”. Diagnostics9 (2020): E723.
- Ceasovschih A., et al. “Improving peripheral artery disease diagnosis: Results of a modern multimarker approach”. Atherosclerosis 275 (2018): E119.
- Tzoulaki I., et al. “C-reactive protein, interleukin-6, and soluble adhesion molecules as predictors of progressive peripheral atherosclerosis in the general population: Edinburgh Artery Study”. Circulation7 (2005): 976-983.
- Kals J., et al. “β2-microglobulin, a novel biomarker of peripheral arterial disease, independently predicts aortic stiffness in these patients”. Scandinavian Journal of Clinical and Laboratory Investigation 4 (2011): 257-263.
- Ceasovschih A., et al. “A six-mounth evaluation of inflammatory biomarkers prognostic predictability in patients with peripheral artery disease”. Atherosclerosise56e (2021): e293.
- Signorelli SS., et al. “Neopterin: a potential marker in chronic peripheral arterial disease”. Molecular Medicine Reports 6 (2013): 1855-1858.
- Fatemi S., et al. “Copeptin, B-type natriuretic peptide and cystatin C are associated with incident symptomatic PAD”. Biomarkers 6 (2019): 615-621.